10. Retèl et al. (2013) Prospective http://www.ejcancer.com/article/S0959-8049(13)00735-1/abstract December, Prspective study 2013 study analysis based on 5-year survival of genomic profiling in date from the RASTER breast cancer. study. Costs and outcomes (QALYs) were calculated for 427 patients (node negatve), subgroup analysis performed based on tumour characteristics. The omission of chemotherapy for patients with a low risk score was both a and oncological safe choice. 11. Review Azim Jr et al. (2011) A review of the February 2, Long-term effects toxic effects of 2011. of adjuvant adjuvant chemotherapy, chemotherapy in breast with focus on adverse cancer. events such as cardiac toxicity, secondary leukaemia, cognitive function, fertility, and neurotoxicity. Categorise trial design, for example meta-analysis, randomised trials, non-randomised trial or observational study, study of diagnostic accuracy, etc.
10. study Retèl et al. (2013) Prspective analysis of genomic profiling in breast cancer. Prospective study based on 5-year survival date from the RASTER study. Costs and outcomes (QALYs) were calculated for 427 patients (node negatve), subgroup analysis performed based on tumour characteristics. The omission of chemotherapy for patients with a low risk score was both a and oncological safe choice. http://www.ejcancer.com/article/S0959-8049(13)00735-1/abstract December, 2013 11. Review Azim Jr et al. (2011) Long-term effects of adjuvant chemotherapy in breast cancer. A review of the toxic effects of adjuvant chemotherapy, with focus on adverse events such as cardiac toxicity, secondary leukaemia, cognitive function, fertility, and neurotoxicity. February 2, 2011. Categorise design, for example meta-analysis, randomised trials, non-randomised trial or observational study, study of diagnostic accuracy, etc. trial
MSAC%20Application%201376.1_MammaPrint%20redacted.docx